Sovremennyy algoritm vedeniya patsientov s sindromom khronicheskogo zapora s pozitsiy vnedreniya novykh farmakologicheskikh preparatov


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article is dedicated to the main pathophysiological aspects of the chronic constipation syndrome (CC) and the application of modern prokinetics (5-HT receptors agonists) in this disorder. The main causes and clinical manifestations of functional CC are presented. Much attention is paid to the role of modern selective prokinetic - 5-HT4-receptor agonist prucalopride, an innovative drug with an attractive safety profile for patients with CC, when dietary measures and laxatives do not provide the desired effect in the elimination of symptoms.

Full Text

Restricted Access

References

  1. Leung L, Riutta T, Kotecha J, Rosser W. Chronic constipation: an evidence-based review. J Am Board Fam Med 2011;24(4): 436-51.
  2. Wong BS, Manabe N, Camilleri M. Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation. Clin Exp Gastroenterol 2010; 3:49-56.
  3. Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003;349:1360-68.
  4. Johanson JF. Review of the Treatment Options for Chronic Constipation. Med Gen Med 2007;9(2):25-40.
  5. Kurniawan I, Simadibrata M. Management of chronic constipation in the elderly. Acta Med Indones 2011;43(3):195-205.
  6. Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther 2010;31:938-49.
  7. Dennison C, Prasad M, Lloyd A, et al. The health-related quality of life and economic burden of constipation. Pharmacoeconomics 2005;23:461-76.
  8. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007;25:599-608.
  9. Tack J, Mueller-Lissner S, Dubois D, Schenck F. Only 27 % of European patients with chronic constipation are satisfied with current treatment options. UEGW/WCOG: Gut 2009;58(II).
  10. Cash BD, Chey WD. The role of serotonergic agents in the treatment of patients with primary chronic constipation. Aliment Pharmacol Ther. 2005;22:1047-60.
  11. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130(5):1377-90.
  12. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130(5):1480-91.
  13. American College of Gastroenterology Chronic Constipation Task Force. Am J Gastroenterol 2005; 100(1):1 -4.
  14. Wald A. Chronic constipation: advances in management. Neurogastroenterol Motil 2007; 19( 1 ):4-10.
  15. Маев И.В., Самсонов А.А. Синдром хронического запора (Алгоритм диагностики и лечебной тактики). Пособие для врачей общей практики, терапевтов, гастроэнтерологов. Учебное пособие. М., 2006. 44 с.
  16. Яковенко Э.П., Агафонова Н.А. Механизмы развития запоров и методы их лечения // Клинические перспективы гастроэнтерологии, гепатологии 2003. № 3. С. 25-32.
  17. Шульпекова Ю.О. Запор и методы его лечения// РМЖ 2006. Т. 8. № 2. С. 90-6.
  18. Velio P, Bassotti G. Chronic idiopathic constipation: pathophysiology and treatment. J Clin Gastroenterol 1996;22:190-96.
  19. Rao SS. Constipation: evaluation and treatment. Gastroenterol Clin North Am 2003;32:659-83.
  20. Arce DA, Ermocilla CA, Costa H. Evaluation of constipation. Am Fam Physician 2002;65:2283-90.
  21. Маев И.В. Хронический запор // Лечащий врач 2001. № 7. C. 53-9.
  22. Koloski NA, Talley NJ, Boyce PM. Chronic Constipation: Health Care Use and Cost Chronic Constipation: Health Care Use and Cost Am J Gastroenterol 2002;97: 2290-99.
  23. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997;32:920-24.
  24. Heaton KW, O'Donnell LJ. An office guide to whole-gut transit time. Patients' recollection of their stool form. J Clin Gastroenterol 1994;19:28-30.
  25. Lacy BE, Levenick JM, Crowell M. Chronic constipation: new diagnostic and treatment approaches. Therap Adv Gastroenterol 2012;5(4):233-47.
  26. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut 1999;45:1137-42.
  27. Pare P. The approach to diagnosis and treatment of chronic constipation: suggestions for a general practitioner. Can J Gastroenterol 2011;25(B):36-40.
  28. Walia R, Mahajan L, Steffen R. Recent advances in chronic constipation. Curr Opin Pediatr 2009;21(5):661-66.
  29. Pampati V, Fogel R. Treatment options for primary constipation. Curr Treatment Options Gastroenterol 2004;7:225-33.
  30. Camilleri M. Serotonergic modulation of visceral sensation: lower gut. Gut 2002; 51:81-6.
  31. Tack J, Janssen P, Wouters M, et al. Targeting serotonin synthesis to treat irritable bowel syndrome. Gastroenterology 2011;141:420-22.
  32. Kim D-Y, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000;95:2698-709.
  33. Hegde SS, Eglen RM. Peripheral 5-HT4 receptors. Faseb J 1996;10:1398-407.
  34. Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 2003;2:25-34.
  35. Gershon MD, Task J. The serotonin signaling system: From basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132: 397-414.
  36. Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012;35(7):745-67.
  37. Quigley EM. Prucalopride: safety, efficacy and potential applications. Therap Adv Gastroenterol 2012;5(1):23-30.
  38. De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008;20:99-112.
  39. Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698-703.
  40. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-54.
  41. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29:315-28.
  42. Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58:357-65.
  43. Van de Velde V, Ausma J, Vandeplassche L. Pharmacokinetics of prucalopride (Resolor®) in man. Gut 2008;57:282.
  44. Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002;16:759-67.
  45. Camilleri M, Deiteren A. Invited Review. Prucalopride for constipation. Exp Opin Pharmacother 2010;11:451-61.
  46. Stanghellini V, Vandeplassche L, Kerstens R. Best Response Distribution Of 12-Week Treatment With Prucalopride (Resolor) In Patients With Chronic Constipation: Combined Results Of Three Randomised, Double-Blind, Placebo-Controlled Phase Iii Trials Gut 2010;59(III):42.
  47. Tack JF, et al. Poster session DDW 2008;T1322.
  48. Kerstens R. 18th UEGW, 23-27 October 2010, Barcelona, Spain, Poster Presentation, 2010:1262.
  49. Galandiuk S, Rykx A, et al. Gut 2008;57 (II):A86.
  50. Tack J, et al. Gastroenterology 2008; 134( 1 ):A530-31.
  51. Camilleri M, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation -follow-up of patients from the pivotal studies Aliment Pharmacol Ther 2010;32: 1113-23.
  52. Camilleri M, Specht Gryp R, Kerstens R, et al. Gastroenterology 2008; 134:548.
  53. World Gastroenterology Organisation Global Guidelines Constipation: a global perspective November 2010.
  54. TA211 Constipation (women) - prucalo-pride: guidance. http://www.nice.org.uk/ nicem edia/li ve/13284/52078/52078.pdf.
  55. Tack J, et al. Neurogastroenterol Motil 2011;23(8):697-710.
  56. Cash BD, Chey WD. Aliment Pharmacol Ther 2005;22:1047-60.
  57. Инструкция по применению препарата Резолор. РУЛП-001413 от 11.01.2012.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies